Newleos Therapeutics Inc.

About Newleos Therapeutics Inc.

Newleos Therapeutics is a clinical-stage biotechnology company focused on providing innovative treatments for mental health conditions. Their mission is to offer a new dawn or 'eos' for the one in eight people worldwide suffering from mental illness, by developing therapies with improved outcomes and reduced side effects compared to current standards of care.

Products & Services

Clinical-stage oral small molecules:Targeting GABAA-γ1, V1a, TAAR1, and GABAA-α5, with first- or best-in-class potential for treating general anxiety, social anxiety, substance use disorders, and cognitive impairment.

Specialties

Neuropsychiatric drug development Innovative mechanisms of action CNS (Central Nervous System) therapies

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 93500000 MR: - FA: $93.5 million FAN: 93500000	D: 2025-02-13 FD: 2025-02-13	5 investors

Series A Latest

2025-02-13

$93.5M

5 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

D

David Donabedian

Founding Chief Executive Officer

F

Federico Bolognani

Co-founder, Chief Medical Officer

W

William Martin

Co-founder, start-up Chief Development Officer

J

John McCabe

Chief Financial Officer

S

Sondra Smyrnios

Senior Vice President, Clinical and Technical Operations

A

Adam Simmons

Vice President, Clinical Operations & Development

View 22 more team members with Pro

Unlock Full Team Directory

Recent News